{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:48:04Z","timestamp":1794023284788,"version":"4.8.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range: 22\u2013210 days) after CAR-T therapy and a median of 85 days after cytokine release syndrome resolution. Gut biopsies uniformly demonstrated inflammation, including intra-epithelial lymphocytosis and villous blunting. In one case where CAR-specific immunofluorescence stains were available, CAR T-cell presence was confirmed within the lamina propria. Systemic corticosteroids were initiated in 10 patients (71%) a median of 25.5 days following symptom onset, with symptom improvement in 40%. Subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. Five patients (36%) have died from bowel perforation or treatment-emergent sepsis. In conclusion, IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy typically beginning 1\u20133 months after infusion. Thorough diagnostic workup is essential, including evaluation for potential T-cell malignancies. The early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.<\/jats:p>","DOI":"10.1038\/s41408-024-01167-8","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:03:06Z","timestamp":1729065786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"given":"Gliceida Galarza","family":"Fortuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-3528","authenticated-orcid":false,"given":"Constanza","family":"Savid-Frontera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M.","family":"Mor\u00e1n-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie N.","family":"Samraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kikkeri N.","family":"Naresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2643-7840","authenticated-orcid":false,"given":"Mariola","family":"Vazquez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Y.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Gubatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"de Menezes Silva Corraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh M.","family":"Kalariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Rodriguez","family":"Valdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sireesha Asoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N. Engl J Med. 2023;388:1002\u201314.","journal-title":"N. Engl J Med"},{"key":"1167_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N. Engl J Med. 2023;389:335\u201347.","journal-title":"N. Engl J Med"},{"key":"1167_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, Gallego Perez-Larraya J, van de Donk N, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"438 e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"9","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transpl Cell Ther. 2023;9:438 e1\u2013438 e16.","journal-title":"Transpl Cell Ther"},{"key":"1167_CR5","first-page":"2443","volume":"141","author":"BD Santomasso","year":"2023","unstructured":"Santomasso BD, Gust J, Perna F. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood. 2023;141:2443\u201351.","journal-title":"Blood"},{"key":"1167_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/COC.0000000000000596","volume":"42","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, et al. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol. 2019;42:789\u201396.","journal-title":"Am J Clin Oncol"},{"key":"1167_CR7","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/ibd\/izaa320","volume":"27","author":"A Hashim","year":"2021","unstructured":"Hashim A, Patten PEM, Kuhnl A, Ooft ML, Hayee B, Sanderson R. Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. Inflamm Bowel Dis. 2021;27:e45\u2013e46.","journal-title":"Inflamm Bowel Dis"},{"key":"1167_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149450","volume":"13","author":"S Zundler","year":"2023","unstructured":"Zundler S, Vitali F, Kharboutli S, Volkl S, Polifka I, Mackensen A, et al. Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. Front Oncol. 2023;13:1149450.","journal-title":"Front Oncol"},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli M, Loughney TM, Deniz E, Chahine JJ, Albitar M, Pittaluga S, et al. Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy. N. Engl J Med. 2024;390:2074\u201382.","journal-title":"N. Engl J Med"},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"1167_CR11","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"Elsallab","year":"2024","unstructured":"Elsallab, Ellithi M, Lunning MA M, D\u2019Angelo, Ma C, Perales MA J, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024;143:2099\u2013105.","journal-title":"Blood"},{"key":"1167_CR12","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","volume":"122","author":"AM Perry","year":"2013","unstructured":"Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122:3599\u2013606.","journal-title":"Blood"},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/mi.2009.106","volume":"2","author":"F Barone","year":"2009","unstructured":"Barone F, Patel P, Sanderson JD, Spencer J. Gut-associated lymphoid tissue contains the molecular machinery to support T-cell-dependent and T-cell-independent class switch recombination. Mucosal Immunol. 2009;2:495\u2013503.","journal-title":"Mucosal Immunol"},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/mi.2016.59","volume":"9","author":"J Spencer","year":"2016","unstructured":"Spencer J, Sollid LM. The human intestinal B-cell response. Mucosal Immunol. 2016;9:1113\u201324.","journal-title":"Mucosal Immunol"},{"key":"1167_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.it.2017.10.006","volume":"39","author":"FL Jahnsen","year":"2018","unstructured":"Jahnsen FL, Baekkevold ES, Hov JR, Landsverk OJ. Do Long-Lived Plasma Cells Maintain a Healthy Microbiota in the Gut? Trends Immunol. 2018;39:196\u2013208.","journal-title":"Trends Immunol"},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.4049\/jimmunol.1003181","volume":"187","author":"L Mesin","year":"2011","unstructured":"Mesin L, Di Niro R, Thompson KM, Lundin KE, Sollid LM. Long-lived plasma cells from human small intestine biopsies secrete immunoglobulins for many weeks in vitro. J Immunol. 2011;187:2867\u201374.","journal-title":"J Immunol"},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1084\/jem.20161590","volume":"214","author":"OJ Landsverk","year":"2017","unstructured":"Landsverk OJ, Snir O, Casado RB, Richter L, Mold JE, Reu P, et al. Antibody-secreting plasma cells persist for decades in human intestine. J Exp Med. 2017;214:309\u201317.","journal-title":"J Exp Med"},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/PAS.0b013e3180cab60c","volume":"31","author":"JA Daniels","year":"2007","unstructured":"Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol. 2007;31:1800\u201312.","journal-title":"Am J Surg Pathol"},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/ajg.2016.329","volume":"111","author":"SF Jorgensen","year":"2016","unstructured":"Jorgensen SF, Reims HM, Frydenlund D, Holm K, Paulsen V, Michelsen AE, et al. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency. Am J Gastroenterol. 2016;111:1467\u201375.","journal-title":"Am J Gastroenterol"},{"key":"1167_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10875-021-01104-5","volume":"42","author":"CM van Schewick","year":"2022","unstructured":"van Schewick CM, Lowe DM, Burns SO, Workman S, Symes A, Guzman D, et al. Bowel Histology of CVID Patients Reveals Distinct Patterns of Mucosal Inflammation. J Clin Immunol. 2022;42:46\u201359.","journal-title":"J Clin Immunol"},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/bloodadvances.2023012336","volume":"8","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Poh C, Hirayama AV, Gauthier J, Cassaday RD, Shadman M, et al. Answering the \u201cDoctor, can CAR-T therapy cause cancer?\u201d question in clinic. Blood Adv. 2024;8:895\u20138.","journal-title":"Blood Adv"},{"key":"1167_CR22","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison SJ, Nguyen T, Rahman M, Er J, Li J, Li K, et al. CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma. Blood. 2023;142:6939.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01167-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01167-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01167-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:05:15Z","timestamp":1729065915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01167-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01167-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB reports consulting: Adaptive Biotech, BMS, Caribou Biosciences, Genentech, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. RF reports consulting: AbbVie, Adaptive, Amgen, Apple, BMS\/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi; Scientific Advisory Board: Caris Life Sciences; Board of Directors: Antengene; Patents for certain FISH tests in MM. CF reports consulting: Janssen; research: Regeneron, Janssen; stock ownership: Affimed. PMV reports consulting: Abbvie, Astra Zeneca, BMS, GSK, Janssen, Karyopharm, Lava Therapeutics, Regeneron, Sanofi; research: Abbvie, Janssen, Regeneron. SDR reports honoraria: Janssen, BMS; steering committee involvement, Gracell Therapeutics, BMS; research support, Janssen, BMS, C4 Therapeutics, Gracell Therapeutics, Heidelberg Pharma; consulting: Genentech, Janssen, BMS. JYS reports consulting: Kite, Immpact Bio. LL reports consulting: Allogene, Sanofi. SFP reports Consulting: Cartography Biosciences; Scientific Advisory Board: Leica Biosystems. JLW reports consulting: Adaptive. AJC reports consulting: BMS, Adaptive; Research: Adaptive Biotechnologies, Harpoon, Nektar, BMS, Janssen, Sanofi, AbbVie. DWS reports consulting: GlaxoSmithKline, Janssen, Sanofi, Abbvie, Bristol Myer Squibb, Pfizer, Bioline, Arcellx, AstraZeneca, Genentech; Research: Gilead, Pfizer, Janssen, Bioline, GlaxoSmithKline, Sanofi, Amgen, Cantex, Arcellx, Roche; Steering Committee: Janssen; Data safety and monitoring: Karyopharm, and Independent Review Committee: Parexel. FLL reports a consulting or advisory role for Allogene, Amgen, Bluebird Bio, Bristol Myers Squibb\/Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja, and Wugen; research funding from Allogene, Kite, and Novartis; and patents, royalties, other intellectual property in the field of cellular immunotherapy. P.V reports consulting or advisory role for Abbvie, AstraZeneca, Karyopharm Therapeutics, Bristol Myers Squibb, Lava Therapeutics, Sanofi, Janssen, GlaxoSmithKline; Research funding from Abbvie, Janssen, GlaxoSmithKline, and TeneoBio; Travel, accommodations, and expenses from Sanofi. DKH reports consulting: BMS, Janssen, legend Biotech, Pfizer, Karyopharm; Research: BMS, Karyopharm, Adaptive Biotechnologies, and Pentecost Myeloma Research Center. The remaining authors have no interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Institutional Review Board approval was obtained for participation within the Consortium at each participating center. Patients signed informed consent at the time of CAR-T referral at each center. No identifiable data or images were shared between centers, and no identifiable data or images are present in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"180"}}